# Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

> **NCT05848206** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 251831 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05848206
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-11
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 251831 (ACTUAL)
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848206, "Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05848206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*